Drug intelligence / Profile preview

TTK peptide

Development stage: Phase 2
Modality: Peptides, Vaccines & Immunotherapeutics
Administration: Subcutaneous

Overview

TTK peptide is an HLA-A*2402 restricted epitope peptide derived from the cancer-specific TTK protein. It is being investigated as a component of a peptide vaccine therapy for esophageal cancer. The peptide aims to induce a tumor-specific cytotoxic T lymphocyte (CTL) response against cancer cells that overexpress the TTK protein.

Targets

TTK (TTK protein kinase)

Beyond the preview

Go deeper on TTK peptide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TTK peptide.

Explore the full profile